Isabel Bover

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.

TL;DR: Dacomitinib demonstrated significantly improved PFS versus erlotinib, with acceptable toxicity, in patients with advanced non-small-cell lung cancer (NSCLC), and PFS benefit was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, EGFR wild- type, and EGFR mutants.

TL;DR: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA and may be a novel surrogate prognostic marker.

TL;DR: CG remains a standard regimen for first-line treatment of advanced NSCLC on the basis of results, and no differences in median survival or time to progression were observed.